+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease



Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease



Neuroimage. Clinical 13: 106-115



We developed a merged younger-older adult template of the fornix and demonstrated its utility for studies of aging and preclinical Alzheimer's disease (AD). In Experiment 1, probabilistic tractography was used to reconstruct the fornix in younger and older adults and successful streamlines were then averaged to create a merged template in standard space. The new template includes the majority of the fornix from the hippocampal formation to the subcallosal region and the thalamus/hypothalamus. In Experiment 2, the merged template was validated as an appropriate measure for studies of aging, with comparisons against manual tracing measures indicating identical spatial coverage in younger and older adult groups. In Experiment 3, the merged template was found to outperform age-specific templates in measures of sensitivity and specificity computed on diffusion tensor imaging data of an independent participant cohort. In Experiment 4, relevance to preclinical AD was demonstrated via associations between fractional anisotropy within the new fornix template and cerebrospinal fluid markers of AD pathology (Aβ42 and the t-tau/Aβ42 ratio) in a third independent cohort of cognitively normal older adults. Our new template provides an appropriate measure for use in future studies seeking to characterize microstructural alterations in the fornix associated with aging and preclinical AD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057605378

Download citation: RISBibTeXText

PMID: 27942453

DOI: 10.1016/j.nicl.2016.11.024


Related references

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia 7(3): 280-292, 2011

Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. Neurology 83(18): 1613-1619, 2014

Development of a mnemonic discrimination task using naturalistic stimuli with applications to aging and preclinical Alzheimer's disease. Learning & Memory 26(7): 219-228, 2019

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology 71(6): 765-775, 2012

Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template. Bioorganic and Medicinal Chemistry Letters 22(14): 4707-4712, 2012

Enhanced mass resolution method development, validation and assay application to support preclinical studies of a new drug candidate. Rapid Communications in Mass Spectrometry 20(8): 1240-1246, 2006

Aging, preclinical Alzheimer disease, and early detection. Alzheimer Disease and Associated Disorders 17(Suppl. 2): S60-S62, 2003

The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimer's and Dementia 10(1): 84-92, 2014

Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Annals of Neurology 45(3): 358-368, 1999

Metabolic brain networks in aging and preclinical Alzheimer's disease. Neuroimage. Clinical 17: 987-999, 2018

Cross-validation of optimized composites for preclinical Alzheimer's disease. Alzheimer's and Dementia 3(1): 123-129, 2017

Aging-3Towards a Cognitive Endophenotype Model of Preclinical Alzheimer's Disease. Archives of Clinical Neuropsychology 30(6): 478.3-479, 2015

Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Annals of Neurology 59(4): 673-681, 2006

APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology 63(5): 816-821, 2004

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging 30(7): 1026-1036, 2009